Skip to content

Author

Ali J. Addie

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#gene editing Review Sep 2026

Light-activated CRISPR/dCas9 nanomedicine for programmable control of renal fibrosis.

It is argued that the most defensible therapeutic objective is not permanent genome editing or autonomous organ regeneration, but spatially confined, temporally limited, and reversible regulation of validated fibrotic or protective gene programs using CRISPRa, CRISPRi, or dCas9-based epigenome editors.

B. Taha, Ali J. Addie, A. Haider et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.